This site is intended for US healthcare professionals only
Mechanism of Action
Optune Lua® uses electrical fields to disrupt cancer cell viability.1
In MPM, only Optune Lua delivers TTFields, which exert antitumor effects by disrupting the activity of cancer cells during multiple phases of mitosis (cell division)1,2,4
TTFields are alternating electric fields delivered at a unique frequency that allows them to selectively disrupt MPM cancer cell division1
Healthy cells have different properties (including division rate, morphology, and electrical properties), than cancer cells, and therefore are not significantly affected by Optune Lua treatment7-12
View TTFields mechanism of action video
This video showcases the detailed process of how TTFields disrupt cancer cell division.
Optune Lua is FDA approaved as first-line therapy together with pemetrexed and platinum-based chemotherapy for patients with MPM1,13
MPM, malignant pleural mesothelioma; TTFields, Tumor Treating Fields
References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2021. 2. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:1-16. doi:10.1038/srep18046 3. Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA. 2007; 104(24):10152-10157. doi:10.1073/pnas.0702916104 4. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64(9):3288-95. doi:10.1158/0008-5472.can-04-0083 5. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):1-20. doi:10.1371/journal.pone.0125269 6. Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191-1204. doi:10.1007/s00262-020-02534-7 7. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 8. Cooper GM. The development and causes of cancer. In: The Cell: A Molecular Approach. 2nd ed. Sinauer Associates; 2000:chap 15. Accessed July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK9963/ 9. Baba AI, Câtoi C. Tumor cell morphology. In: Comparative Oncology. The Publishing House of the Romanian Academy; 2007:chap 3. Accessed July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK9553/ 10. Trainito CI, Sweeney DC, Čemažar J, et al. Characterization of sequentially-staged cancer cells using electrorotation. PLoS One. 2019;14(9):1-18. doi:10.1371/journal.pone.0222289 11. Haemmerich D, Schutt DJ, Wright AW, Webster JG, Mahvi DM. Electrical conductivity measurement of excised human metastatic liver tumours before and after thermal ablation. Physiol Meas. 2009;30(5):459-466. doi:10.1088/0967-3334/30/5/003 12. Ahmad MA, (IEEE SM), Al Natour Z, Mustafa F, Rizvi TA. Electrical characterization of normal and cancer cells. IEEE Access. 2018;6:25979-25986. doi:10.1109/ACCESS.2018.2830883 13. FDA Approves the NovoTTF- 100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019.